FDA advances brigatinib for frontline lung cancer treatment, plus more top stories in hematology/oncology
Brigatinib was granted priority review by the FDA as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. It was the top story in hematology/oncology last week.
Another top story included interim results of the phase 2 TALAPRO-1 study that showed the PARP inhibitor talazoparib (Talzenna, Pfizer Oncology) was active and safe in certain men with metastatic prostate cancer.
FDA grants priority review to brigatinib for first-line treatment of ALK-positive lung cancer
The FDA granted priority review to brigatinib as first-line treatment for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, according to the agent’s manufacturer.
Talazoparib active, safe among subset of men with metastatic prostate cancer.Talazoparib monotherapy induced promising antitumor activity in men with metastatic castration-resistant prostate cancer who previously received docetaxel, according to the first interim analysis of the single-arm, phase 2 TALAPRO-1 study presented at Genitourinary Cancers Symposium
Post a Comment